316 related articles for article (PubMed ID: 21679419)
1. Herpes zoster in Germany: quantifying the burden of disease.
Ultsch B; Siedler A; Rieck T; Reinhold T; Krause G; Wichmann O
BMC Infect Dis; 2011 Jun; 11():173. PubMed ID: 21679419
[TBL] [Abstract][Full Text] [Related]
2. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Köster I; Reinhold T; Siedler A; Krause G; Icks A; Schubert I; Wichmann O
Eur J Health Econ; 2013 Dec; 14(6):1015-26. PubMed ID: 23271349
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of herpes zoster vaccine in Canada.
Najafzadeh M; Marra CA; Galanis E; Patrick DM
Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
[TBL] [Abstract][Full Text] [Related]
5. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.
Schmidt-Ott R; Schutter U; Simon J; Nautrup BP; von Krempelhuber A; Gopala K; Anastassopoulou A; Guignard A; Curran D; Matthews S; Espié E
J Infect; 2018 May; 76(5):475-482. PubMed ID: 29428228
[TBL] [Abstract][Full Text] [Related]
6. Herpes zoster and postherpetic neuralgia in Catalonia (Spain).
Salleras L; Salleras M; Salvador P; Soldevila N; Prat A; Garrido P; Domínguez A
Hum Vaccin Immunother; 2015; 11(1):178-84. PubMed ID: 25483532
[TBL] [Abstract][Full Text] [Related]
7. Incidence of herpes zoster and its complications in Germany, 2005-2009.
Hillebrand K; Bricout H; Schulze-Rath R; Schink T; Garbe E
J Infect; 2015 Feb; 70(2):178-86. PubMed ID: 25230396
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
11. Burden of disease from shingles and post-herpetic neuralgia in the over 80 year olds in the UK.
Matthews I; Duong M; Parsons VL; Nozad B; Qizilbash N; Patel Y; Guimicheva B
PLoS One; 2020; 15(2):e0229224. PubMed ID: 32097441
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of the cost effectiveness of herpes zoster vaccination.
Szucs TD; Pfeil AM
Pharmacoeconomics; 2013 Feb; 31(2):125-36. PubMed ID: 23335045
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
[TBL] [Abstract][Full Text] [Related]
14. Herpes zoster vaccine: A health economic evaluation for Switzerland.
Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
[TBL] [Abstract][Full Text] [Related]
15. [Herpes Zoster and its prevention in Italy. Scientific consensus statement].
Franco E; Gabutti G; Bonanni P; Conversano M; Stefano Valente ME; Ferro A; Icardi G; Antonio Volpi ML; Maggi S; Rossi A; Scotti S; Vitale F; Greco D;
Ig Sanita Pubbl; 2014; 70(1):111-27. PubMed ID: 24770367
[TBL] [Abstract][Full Text] [Related]
16. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
[TBL] [Abstract][Full Text] [Related]
17. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012.
Yanni EA; Ferreira G; Guennec M; El Hahi Y; El Ghachi A; Haguinet F; Espie E; Bianco V
BMJ Open; 2018 Jun; 8(6):e020528. PubMed ID: 29880565
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
Le P; Rothberg MB
Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
[TBL] [Abstract][Full Text] [Related]
19. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.
Johnson RW
Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study.
Gialloreti LE; Merito M; Pezzotti P; Naldi L; Gatti A; Beillat M; Serradell L; di Marzo R; Volpi A
BMC Infect Dis; 2010 Aug; 10():230. PubMed ID: 20682044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
